List view / Grid view
Filter the results
In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…
Although three-dimensional (3D) printing has been around for some time, many people still underestimate its capabilities. This article addresses the regulatory challenges faced by the pharmaceutical sector and aims to correct some of the most common myths surrounding the technology.
Effective supply chain management can cut costs, improve service and enhance company revenues; however, the pharma industry has historically been a slow adopter of leading-edge practices. Nikki Withers discussed the fundamentals of contemporary supply chain management with Ed Sweeney, Professor of Logistics and Systems at Aston University, who believes that…
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
The European medical cannabis market lacks a common regulatory framework; Peter Kohut charts a route through the complexity and highlights opportunities for the taking.
Pembrolizumab with pemetrexed and platinum chemotherapy has been recommended by NICE to treat non-squamous, non-small cell lung cancer.
Bhavesh Patel, Cécile Matthews and Owen Male at CRA’s Life Sciences Practice assess the relationship between drug pricing for rare disease therapies and disease prevalence in Europe, taking a closer look at payer assessments of orphan drugs in Germany.
Report finds 2020 was a record-breaking year for investment in UK biotech, driven by innovation and the COVID-19 pandemic, with growth anticipated to continue into 2021.
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
A new report suggests artificial intelligence (AI) will be the most disruptive technology in the pharmaceutical industry this year and beyond.
The EMA has accepted Global Blood Therapeutics' marketing authorisation application for Oxbryta (voxelotor) to treat haemolytic anaemia in sickle cell disease.
AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).